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CHARACTERIZATION OF THE IN VITRO GROWTH AND 
DIFFERENTIATION CAPABILITIES OF HUMAN ADIPOSE-DERIVED 
MESENCHYMAL PROGENITOR CELLS 
PANTOS ANGELO SKRITAKIS 
ABSTRACT 
Background: Human mesenchymal progenitor cells are multipotent cells that can be 
harvested from various adult and fetal tissues. They exhibit the potential to differentiate 
into several cell lineages, most notably osteogenic, chondrogenic, and adipogenic 
lineages. Conditions such as osteoporosis, metabolic disease, and arthritis are examples 
of dysfunction of tissues formed by the mesenchyme. The inability of these conditions to 
be healed by the body’s own mechanisms has raised considerable interest in the potential 
of using mesenchymal progenitor cells as a therapeutic intervention. This concept opens 
the possibility of harvesting mesenchymal progenitor cells from an individual, growing 
them into the desired tissue, and implanting them back into the individual. Treatment of 
this nature is much less invasive than current methods, overcomes rejection by the 
immune system, and could potentially demonstrate better outcomes in individuals 
suffering from degenerative disease of the mesenchyme.   
Aims/Objectives: The aims of this study were to determine and to characterize the 
differentiation of human adipose-derived mesenchymal progenitor cells into osteocytes, 
chondrocytes, and adipocytes. The differentiation capacity of the mesenchymal 
progenitor cells was evaluated through cell staining, immunofluorescence, and RNA 
sequencing. 
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Methods: Subcutaneous adipose tissue was collected from patients undergoing elective 
panniculectomies. The abdominal panniculus was liposuctioned, and small explants of fat 
were embedded in Matrigel. Mesenchymal progenitor cells were extracted from the 
explants and plated for differentiation into osteogenic, chondrogenic, and adipogenic 
lineages. Control cells were grown in parallel in basal media to confirm differentiation. 
Dye staining for differentiation was performed with Alizarin Red S, Alcian Blue, and Oil 
Red O, and immunofluorescence staining was performed to indicate lineage-specific 
markers for differentiation.  RNA sequencing was also completed on the different cell 
lineages. 
Results: Human adipose-derived mesenchymal progenitor cells displayed the capacity to 
differentiate into osteogenic, chondrogenic, and adipogenic lineages as evidenced by dye 
staining. Osteogenic differentiation was confirmed with Alizarin Red S staining of 
calcium deposits in the differentiated cells, whereas staining in the control resulted in no 
calcium deposits. Alcian Blue staining confirmed chondrogenic differentiation as 
glycoproteins secreted by the differentiated cells were evident and different in 
morphology compared with the control cells. Oil Red O staining indicated adipogenic 
differentiation by showing lipid droplets in the differentiated cells and no lipid droplets in 
the control. RNA sequencing provided support that lineage differentiation was successful. 
Immunofluorescence staining further proved that differentiated cells expressed lineage-
specific proteins and demonstrated morphological differences. 
Conclusions: This study demonstrates that mesenchymal progenitor cells harvested from 
human adipose tissue have the potential to differentiate into adipogenic, chondrogenic, 
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and osteogenic cell lineages when induced with differentiation media. The differentiation 
of these cells can be assessed with dye staining, RNA sequencing, and 
immunofluorescence staining methods. Further studies should be done to investigate the 
potential of mesenchymal progenitor cells for therapeutic interventions in the treatment 
of various illnesses related to the mesenchyme.  
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INTRODUCTION 
 
Mesenchymal Progenitor Cell Differentiation Capabilities 
 Mesenchymal progenitor cells embryologically originate from the mesoderm and 
are responsible for forming the mesenchyme of an organism (Baksh, Song, & Tuan, 
2004). Thus, they are multipotent stromal cells capable of differentiating into cells of the 
connective tissue (Hwang, Zhang, & Varghese, 2009). True mesenchymal progenitor 
cells are capable of differentiating into three distinct lineages: osteocytes, chondrocytes, 
and adipocytes. However, recent studies have found that they display the ability to 
differentiate into various cells such as myocytes and neurons (Summer & Fine, 2008). 
There are several locations in the body, including bone marrow, adipose tissue, umbilical 
cord, and the placenta, where mesenchymal progenitor cells can be found and easily 
harvested (Squillaro, Peluso, & Galderisi, 2016). Within all of these locations, 
mesenchymal progenitor cells retain the ability to self-renew (Han, Kwon, & Park, 2017). 
This property is extremely practical in using them as a model because they can be 
cultured, expanded, and maintained in vitro. Furthermore, these cells have a unique 
characteristic in that they are able to avoid immune system reaction by downregulating or 
blocking certain proteins such as tumor necrosis factor alpha (Ortiz et al., 2007). This 
property has made them a popular area of research in cell-based regenerative therapy.  
 Mesenchymal progenitors have the capacity to differentiate into adipocytes. 
Adipocytes are specialized cells that function as energy storage cells. They store 
chemical energy in the form of triglycerides. Adipocytes are capable of expanding their 
 2 
storage capacity in one of two ways: hypertrophy, which is defined as an increased size, 
or hyperplasia, which is defined as an increase in the number of adipocytes from 
precursor cells (Tchkonia et al., 2013). Adipogenic hyperplasia occurs through a phase of 
growth arrest and differentiation activated by transcription factors such as peroxisome 
proliferator-activated receptor-γ and CCAAT/enhancer binding proteins (Gregoire, Smas, 
& Sul, 1998).  
White adipocytes are functional differentiated fat cells used primarily for energy 
storage. They require an extensive vascular network that brings nutrients, removes waste 
byproducts, and allows for the delivery of adipose tissue-specific cytokines (adipokines). 
Extreme hypertrophic expansion of adipose has the ability to compromise the vital 
vascular network. As a result of this process, the adipose tissue becomes hypoxic, leading 
to cellular necrosis, adipokine release, and inflammation (Pasarica et al., 2009). This 
vasculature is also required for adipose tissue to function as an endocrine gland. Adipose 
tissue, the largest endocrine organ in the body, is capable of producing hormones, growth 
factors, and adipokines such as leptin and adiponectin (Cao, 2007). Leptin, adiponectin, 
and insulin are important hormones that interact with adipose tissue. Leptin is known to 
inhibit hunger, adiponectin is known to be a regulator of glucose and fatty acid oxidation, 
and insulin is known to store glucose. These compounds are only some of the hormones 
vital to maintaining metabolic homeostasis. Dysregulation of these hormones can also 
lead to metabolic diseases.  
 Chondrocytes are another type of cell that can arise from mesenchymal progenitor 
cells. Chondrocytes are specialized cells that play a major role in the production and 
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secretion of extracellular matrix, which is the key component of cartilage. During 
chondrocyte differentiation, mesenchymal progenitor cells condense under the influence 
of the nuclear transcription factor called SRY (sex-determining region Y)-box 9, or Sox9. 
In conjunction with Sox9, L-Sox5 and Sox6 are expressed to allow terminal chondrocyte 
differentiation to occur (Goldring, Tsuchimochi, & Ijiri, 2006). These transcription 
factors also allow for the expression of cartilage-specific proteins, especially collagen II. 
Hyaline cartilage, fibrous cartilage, and elastic cartilage are three distinct types of 
cartilage found in the body. All cartilage is composed of proteoglycans and collagens. 
The main proteoglycan in cartilage is aggrecan, and the main collagen is collagen II, thus 
making both components important indicators of the presence of chondrocytes (Wilson, 
Belluoccio, & Bateman, 2008).  
Cartilage has many mechanical properties in response to friction, compression, 
shear loading, and tensile loading. Other cartilage is also vital to bio-lubrication in joints. 
However, one of the drawbacks of cartilage is that it lacks the capacity to repair itself 
without a direct vascular supply (Armiento, Stoddart, & Alini, 2018). Because cartilage is 
avascular, it requires the exchange and transport of nutrients, gases, and metabolic 
byproducts by continuous diffusion to nearby vasculature (Ge et al., 2006). Damage to 
cartilage can be detrimental, particularly as the formation of cartilage primarily occurs 
primarily during the early phases of skeletal formation during embryogenesis (Goldring 
et al., 2006). When cartilage is damaged, it may lead to scarring or degeneration, 
resulting in dysfunctionality, pain, or immobility. This situation has made damaged 
cartilage difficult to treat and an area of extreme interest over the past few years.  
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 Osteoblasts are responsible for secreting components that comprise bone and can 
also be derived from mesenchymal progenitor cells. Wnt signaling upregulates the 
expression of the Runt-related transcription factor 2 (Runx2) genes, which along with 
osterix are the main regulators driving osteoblast differentiation. Transforming growth 
factor β then interacts with its receptor, causing osteoblast recruitment to the site of bone 
formation. At this site, fibroblast growth factors are secreted and bind cell-surface 
tyrosine kinase receptors that begin to regulate ossification (Heino & Hentunen, 2008). 
During the production of the bone matrix, the osteoblasts secrete proteins such as alkaline 
phosphatase, an essential enzyme used in mineralization. Similarly, osteonectin is a 
protein associated with calcifying collagen to bone and forming the extracellular matrix. 
Ostepontin is secreted to function as an extracellular linking molecule. When osteoblasts 
become embedded in the matrix that they have secreted, they are considered mature 
osteocytes (Schaffler, Cheung, & Majeska, 2014). Upon maturation into osteocytes, they 
reduce in size, and the number of organelles in the cell decreases, leading to a reduction 
in protein synthesis and secretion.  
Osteocytes function as mechanosensors and regulators of the bone. To 
communicate, they have long cytoplasmic extensions called canaliculi that form networks 
within the bone (Schaffler & Kennedy, 2012). They dictate bone remodeling through 
control of osteoblasts and osteoclasts, which are cells that function in bone resorption 
(Florencio-Silva, Sasso, & Sasso-Cerri, 2015). Osteocytes regulate bone remodeling by 
secreting the protein called receptor activator of nuclear factor kappa-B ligand (RANKL). 
RANKL binds to its receptor (receptor activator of nuclear factor kappa-B, or RANK) on 
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the surface of osteoclasts and stimulates release of bone resorption protein (Schaffler et 
al., 2014). Osteocytes are thus important regulators of bone and matrix mineralization. 
 
Degenerative Diseases Associated With the Mesenchyme 
 The mesenchyme is instrumental in developing into connective tissues and 
skeletal tissues. Wear and tear on bones and joints can cause several diseases to manifest 
themselves over the years as an individual ages. Osteoporosis, which is caused by bones 
becoming more porous and fragile, is a major pathology associated with reduced bone 
mass, impaired bone quality, and a higher risk of fracture (Sözen, Özışık, & Başaran, 
2017).  This disease occurs when bone remodeling results in a net loss due to resorption 
exceeding the level of formation. Data collected in 2010 indicated that 10.2 million adults 
were estimated to have osteoporosis and that the number was expected to grow to 13.6 
million by 2030. Even more concerning, it was estimated that 43.4 million adults had the 
precursor to osteoporosis and that the figure was expected to grow to 57.8 million adults 
in 2030 (https://www.boneandjointburden.org). These details show how bone 
degeneration and osteoblast dysregulation are especially important in an older population.  
Osteoblasts require nutrients and hormone signaling for growth and maintenance. 
During osteoblast differentiation, glycolysis has emerged as the major metabolic pathway 
for meeting energy demands. If the demands are not met, then osteoblast dysfunction 
occurs, which can lead to osteoporosis (Lee, Guntur, & Long, 2017). Similarly, hormones 
such as parathyroid hormone and calcitonin are important modulators of osteoblast 
function and are needed to balance calcium levels. Calcitonin is responsible for inhibiting 
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bone resorption through the osteoclast and for allowing the osteoblast to use calcium 
stores to form bone (Carter & Schipani, 2006). Parathyroid hormone functions by binding 
directly to parathyroid hormone receptors on osteoblasts. This causes the secretion of 
RANKL and the subsequent initiation of “osteocytic osteolysis,” a process in which 
osteocytes signal to osteoclasts to resorb the bone matrix when the demand for calcium in 
the body increases (Rosen, 2000). An understanding of these models helps us to elucidate 
the important mechanisms of osteocyte regulation from the progenitor state to the 
maturation state.  
 Another major health concern involving mesenchymal degeneration is rheumatoid 
arthritis. In 2011 alone, it directly cost the United States $6.7 billion in the treatment of 
rheumatoid arthritis (https://www.boneandjointburden.org). In this pathology, the 
immune system attacks the joints, leading to inflammation, pain, and edema. Cytokine 
analysis of messenger RNA (mRNA) and protein in rheumatoid arthritis tissue displayed 
many proinflammatory cytokines such as tumor necrosis factor alpha, interleukin 1, and 
interleukin 6. However, the compensation mechanism of anti-inflammatory cytokine 
release of interleukin 10 and transforming growth factor beta 1 is not sufficient (Feldman, 
Brennan, & Maini, 1996). These proinflammatory cytokines cause leukocyte 
accumulation through cell migration rather than proliferation, leading to synovitis 
(McInnes & Schett, 2011). The body attempts to balance the immune response, and 
studies found that mast cell activation significantly reduces the levels of tumor necrosis 
factor alpha and interleukin 1 (Woolley & Tetlow, 2000).  
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When surgical intervention becomes the necessary treatment of this disease, the 
options are limited to cartilage repair or cartilage restoration. Reparative procedures for 
cartilage-based injuries are the preferred method of intervention (Jansen et al., 2019). 
Restorative procedures, the other method of intervention, have yet to be effectively 
developed. Obstacles such as optimizing chondrogenic cell phenotype, cartilage 
production, cartilage stability, cartilage integration, and delivery of antioxidants and anti-
inflammatory factors are still being addressed (Tuan, Chen, & Klatt, 2013). Construction 
of a model in which differentiating progenitor cells lead to functional chondrocytes in 
vitro can only help in understanding the mechanism of chondrogenesis. 
 
Adipose Tissue at the Center of Metabolic Disease 
 Adipocytes comprise the majority of adipose tissue and are a critical component 
of regulating systemic metabolism. In response to excess caloric intake, white adipocytes 
expand in size to store excess energy. Obesity occurs when adipose tissue expansion 
becomes excessive, leading to chronic inflammation as well as insulin resistance. This 
condition occurs by a mechanism of DNA release through degenerating adipocytes, 
hypoxic conditions, and adipokine release, which stimulates immune system responses 
(Nishimoto et al., 2016; Pasarica et al., 2009). When adipose tissue expands, there must 
be an expansion in the vascular network that supplies the tissue. Dysregulation of this 
vasculature can lead to metabolic diseases (Gealekman et al., 2011). Treatment for 
obesity has not been an easy task. Studies on adoption, implementation, and maintenance 
of prevention interventions showed that careful monitoring of several dynamics and 
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critical adjustments to keep the prevention plan in place are essential for success (Jalili et 
al., 2019). A strained metabolism, potentially arising from obesity, may lead to 
dysregulation of adipose tissue and an increased risk of developing conditions such as 
heart disease and type II diabetes, which has become a major health concern. Data from 
2013 showed an 8.3% global prevalence of diabetes in adults aged 20-79, and this 
alarming number is expected to rise to 10.1% by 2035 (Forouhi & Wareham, 2014).  
Type II diabetes is a chronic metabolic disorder that arises from the inability to 
secrete sufficient insulin or the inability to respond to insulin secretion. Insulin resistance 
is implicated in several other conditions such as nephropathy, essential hypertension, 
dyslipidemia, non-alcoholic fatty liver disease, and systemic inflammation (Kharroubi & 
Darwish, 2015). In fact, one of the hallmarks of metabolic disease is chronic low levels of 
inflammation resulting from the dysfunction of adipose vasculature (Ghaben & Scherer, 
2019). This inflammatory state is triggered by macrophage invasion which inhibits the 
formation of mature adipocytes (Lacasa, Taleb, & Keophiphath, 2007). Treatment for 
obesity and type II diabetes typically focus on prevention and lifestyle changes; however, 
when that is not sufficient, self-management of glucose levels becomes the primary form 
of treatment. Autonomy support from health care professionals has shown significantly 
better self-care and glycemic control (Lee, Piette, & Heisler, 2019). Nevertheless, 
metabolic disease continues to grow, and new forms of therapeutic interventions are 
being pursued.  
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Potential of Using Mesenchymal Progenitor Cells as a Therapeutic 
 As the prevalence of disease increases, so too must the methods of intervention. 
Medicine evolves in order to treat various illnesses in a more efficient and effective 
manner. One concept that has been gaining traction is the use of mesenchymal progenitor 
cells. In the case of metabolic disease from adipose tissue dysfunction, there is great 
potential in the use of mesenchymal progenitor cells. There are other types of adipocytes, 
one of which is the brown adipocyte. This cell is implicated in thermogenesis and is 
known for its numerous mitochondria and highly expressed mitochondrial protein, 
uncoupling protein-1. This protein allows the cell to convert triglycerides into energy in 
the form of heat (Seale & Lazar, 2009).  
Another unique adipocyte mimics white adipocytes by expressing low basal levels 
of uncoupling protein-1, but upon stimulation, it expresses high levels of uncoupling 
protein-1 and induces lipolysis (Wu et al., 2012). This adipocyte is “beige” because it 
originates from white adipose tissue but is functionally similar to brown adipose tissue. 
These cells are believed to help maintain a phenotype presenting as lean and 
metabolically healthy. Because this type of fat is necessary for maintaining body 
temperature, studies have been done to determine whether cold exposure could affect 
brown adipose tissue activity. Results showed that cold-activated brown adipose tissue 
does in fact control energy use and adiposity in humans (Saito et al., 2009). This 
approach would present several challenges as a therapeutic. Research has shown that 
“beige” adipocytes can be grown in vitro and that implanting these cells into a mouse 
model can improve metabolic homeostasis (Min et al., 2016). Understanding this 
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mechanism has the potential to transform into a form of treatment. It has been shown that 
brown fat cells can arise from the vascular endothelium of adipose tissue. Stimulating 
brown adipogenesis from the vasculature could potentially be a therapeutic intervention. 
As another approach, endothelial cells have the capacity to be converted into multipotent 
stem cells, and these cells could then be used to act in a therapeutic manner (Medici et al., 
2010). Manipulation of progenitor cells residing within the human body could act as a 
method of treatment.  
 Mesenchymal progenitor cell therapy has already become a possibility in science. 
Human adipose-derived mesenchymal stromal cells were found to respond to 
chondrogenic differentiation and to show similarities in monolayer culture compared with 
cartilage-derived progenitor cells; however, they were not able to recreate a mature 
extracellular matrix (Baptista et al., 2013). These results demonstrate that there is a future 
in developing bioengineered products. Other work has discovered markers on 
chondrocytes to allow for characterizing which chondrocytes can be enriched for higher 
chondrogenic capacity (Grogan et al., 2007). Nevertheless, bioengineering has many 
obstacles to overcome as evidenced by the attempt to generate grafts for laryngotracheal 
reconstruction (Henderson et al., 2007). In this study, the created cartilage lacked the 
mechanical integrity and stiffness necessary to pass testing. Thus optimization was still 
required before the bioengineered cartilage could be applied. Optimizing the process and 
studying how regenerative medicine could be applied allowed researchers in a study of 
tendon repair to discover that using mesenchymal stem cells in conjunction with other 
components resulted in failure forces greater than peak in vivo forces (Butler et al., 2008). 
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Although promising work has been done, there is room for improvements, and safety 
studies are still required to be performed prior to any clinical trials.  
 Using mesenchymal progenitor cells as a therapeutic is still highly investigated. 
One of the central characteristics of progenitor cells is the benefit of immuneprivilege. 
Allogeneic mesenchymal cells do not activate the immune system during implantation. A 
study done with allogeneic mesenchymal stem cells determined that a bone defect in dogs 
could be successfully treated without the use of immunosuppressive therapy (Arinzeh et 
al., 2003). During tissue repair or transplants, one issue that needs to be monitored is 
local inflammation. Arthroscopic osteochondral autologous transplantation is already an 
approved form of treatment for individuals with articular cartilage injury (Pan, Chen, & 
Feng, 2019). Patients undergoing microfracture, autologous chondrocyte implantation, 
osteochondral autograft transplantation, and osteochondral allograft procedures had an 
average reoperation rate of 15% at 2 years (Frank et al., 2018). This has been shown to be 
a short-term effective treatment and is proof that immune system reactions would not 
cause adverse events. Understanding the mechanisms of immune-privilege grafts would 
further assist in bioengineering tissues that could be used in a clinical setting. 
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SPECIFIC AIMS AND OBJECTIVES 
 
 Human mesenchymal progenitor cells are unique multipotent cells. They have the 
capacity to differentiate into the components of the mesenchyme. Dysfunction and 
dysregulation of the mesenchyme lead to pathologies that present themselves in the 
clinics. Understanding the mechanisms of differentiation and manipulating their 
differentiation capabilities present a potential as a therapeutic intervention. Harvesting 
these cells from donors and culturing them in Matrigel could be instrumental in 
maintaining multipotency and successful differentiation.   
This study seeks to determine and to characterize the differentiation of human 
adipose-derived mesenchymal progenitor cells into osteocytes, chondrocytes, and 
adipocytes. The objectives of this study are to assess the differentiation capacity of 
mesenchymal progenitors through cell staining, immunofluorescence staining, and RNA 
sequencing. 
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METHODS 
 
Collection and Storage of Human Adipose-Derived Mesenchymal Progenitor Cells 
Adipose Tissue Expansion Assay 
Samples of subcutaneous adipose tissue were obtained from patients undergoing 
panniculectomies. The specimens were taken after the donors consented in accordance 
with the University of Massachusetts Institutional Review Board (University of 
Massachusetts, Worcester, MA). The abdominal pannus was liposuctioned to collect 
lipoaspirate. Syringes were filled with the lipoaspirate and centrifuged for 5 minutes at 
500 x g. After the pellet containing blood and vessel-filled fat was discarded, the middle 
fat layer was washed with basal endothelial growth media. The suspension was 
centrifuged for 5 minutes at 500 x g, and then the media and cell pellet were aspirated. 
The fat was washed again with basal endothelial growth media and spun at 500 x g for 5 
minutes. The media was aspirated, and the fat was poured into petri dishes with basal 
endothelial growth media. Approximately 250-300 pieces of fat (about 1 mm3) were 
selected and embedded in Matrigel (Corning Life Sciences, Tewksbury, MA; catalog # 
356231). The plates were placed into a 37 °C incubator for 30 minutes to allow Matrigel 
to polymerize. After 30 minutes, growth media comprised of basal endothelial growth 
media, 5% GenClone™ fetal bovine serum (FBS) (Genesee Scientific, San Diego, CA; 
catalog #25-514), 1% penicillin-streptomycin (Pen-Strep) (Gibco/Thermo Fisher 
Scientific, Waltham, MA; catalog #15140-122), 1 g/L glucose (Sigma-Aldrich, St. Louis, 
MO; catalog #G8270), and 0.2% Normocin™ antimicrobial reagent (InvivoGen, San 
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Diego, CA; catalog #ant-nr-2). Media was also supplemented with a cocktail of 
proangiogenic growth factors including recombinant human endothelial growth factor 
(Gibco/Thermo Fisher Scientific, Waltham, MA; catalog #PHG0311), recombinant 
human R3 insulin-like growth factor-1 (Sigma-Aldrich, St. Louis, MO; catalog #I1271), 
recombinant human vascular endothelial growth factor (R&D System, Minneapolis, MN; 
catalog #4644VS), and recombinant human basic fibroblast growth factor (R&D System, 
Minneapolis, MN; catalog #233-FB). The next morning, a full media change was 
performed with fresh growth media. For 14 days in culture, half of the growth media was 
changed every other day.  
Expanded Stromal Vascular Fraction Collection 
After 14 days, all of the growth media was removed, and the plates were washed 
twice with Dulbecco’s phosphate-buffered saline (DPBS) (1X) (Gibco/Thermo Fisher 
Scientific, Waltham, MA; catalog #14190250). Filter-sterilized dispase (Corning Life 
Sciences, Tewksbury, MA; catalog # 354235) was added to the plates, and the plates 
were incubated at 37 °C for 40 minutes. The Matrigel was disrupted by pipetting the 
dispase/cell mix to help break up the Matrigel. The plates were further incubated for 20 
minutes. If lumps of Matrigel were still present, the plates were placed back in the 
incubator in 10-minute increments. After all the Matrigel was digested, trypsin-
ethylenediaminetetraacetic acid (EDTA) (10X) (Gibco/Thermo Fisher Scientific, 
Waltham, MA; catalog #15400-054) was added to the plates, and the plates were 
incubated at 37 °C for 3 minutes. The explant/cell/dispase mixture was collected in 
conical tubes, filled with endothelial growth media, and spun at 500 x g for 10 minutes. 
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Floating explants and media were discarded. The pellet was resuspended with growth 
media and subsequently spun at 500 x g for 10 minutes. The media was aspirated, and the 
pellet was resuspended in growth media and placed in culture plates overnight in the 37 
°C incubator. The next morning, a full media change was performed on the plates. After 
72 hours of total incubation time, the media was aspirated, and the plates were washed 
twice with phosphate-buffered saline (PBS). Trypsin (1X) was added to the plates, and 
the plates were incubated for 10 minutes at 37 °C. After all the cells dissociated from the 
plates, the cell/trypsin mixture was collected with equal volume of growth media in a 
conical tube. The cells were spun for 10 minutes at 500 x g, and the trypsin media was 
aspirated. The pellet was resuspended in growth media, placed on a cell culture plate, and 
incubated overnight at 37 °C. The next morning, half of the growth media was replaced 
with new growth media. Seventy-two hours after plating, cells were collected to be 
frozen.  
Cell Freezing  
In preparation for freezing the cells, the growth media was removed, and the 
plates were washed twice with PBS. Trypsin was diluted 1:10 in sterile PBS and added to 
the plates. The plates were then incubated for 5 minutes. An equal volume of growth 
media was added to deactivate the trypsin. The cells and media were transferred to a 
conical tube, counted using a hemocytometer, and spun at 500 relative centrifugal force 
(RCF) for 10 minutes. The cell pellets were placed on ice immediately after spinning. 
The media was aspirated, and then the cell pellet was resuspended with freezing media 
composed of 90% FBS and 10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO; 
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catalog #RNBG0369). The suspension was placed into freezing vials at a cell density of 
approximately 6 x 106 cells/mL. The freezing vials were placed in -80 °C overnight. After 
24 hours, the vials were transferred to storage in liquid nitrogen. 
Cell Revival for Experimentation 
Before thawing the cells from liquid nitrogen, fresh growth media was placed in 
the incubator for 30 minutes to allow equilibration. A freezing vial was removed from the 
liquid nitrogen and thawed in the palm of the hand until an “iceberg” formed in the vial. 
The thawed cells were added to the warmed growth media in a conical tube and spun at 
500 RCF for 10 minutes. The media was aspirated, and the pellet was resuspended in 
fresh growth media. The suspension was plated on a cell culture plate and placed in the 
incubator overnight. At 24 hours after plating the thawed cells, a full media change was 
performed with growth media. At 72 hours after seeding, the media was removed from 
the plates, and the plates were washed twice with PBS. After trypsin was diluted 1:10 in 
PBS and added to the plates, the plates were incubated for 5 minutes. An equal volume of 
growth media was added to deactivate the trypsin. The cells and media were collected in 
a conical tube and spun at 500 RCF for 10 minutes. The media was aspirated, the pellet 
was resuspended in fresh growth media, and the cells were counted in a hemocytometer. 
These cells were then used in the adipogenic, chondrogenic, and osteogenic 
differentiation experiments.  
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Adipogenic Differentiation and Staining 
 The cells were plated at a density of 5.5 x 104 cells/cm2. Twenty-four hours after 
the cells were plated from the suspension in a 12-well plate, a full growth media change 
was performed. The next morning, the wells were washed twice with PBS, and a stock 
adipogenic cocktail (2X) was added consisting of Dulbecco’s Modified Eagle Medium 
(DMEM), high glucose (Gibco/Thermo Fisher Scientific, Waltham, MA; catalog 
#11965092), supplemented with 0.2% Normocin™ antimicrobial reagent, 10% FBS, 0.5 
mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich, St. Louis, MO; catalog #I5879), 1 μM 
dexamethasone (Sigma-Aldrich, St. Louis, MO; catalog #D1756), 1 μg/mL insulin 
(Sigma-Alrich, St. Louis, MO; catalog #15500), and 1% Pen-Strep. Half of the 
adipogenic media was changed daily for 72 hours. After 72 hours, the adipogenic media 
was removed and replaced every other day with DMEM supplemented with 10% FBS, 
1% Pen-Strep, and 0.2% Normocin™ antimicrobial reagent for 7 days. 
 Before staining the cells with Oil Red O, the media was aspirated, 10% formalin 
was added, and the wells were incubated for 5 minutes at room temperature. The formalin 
was removed, and fresh formalin was added for 1 hour at room temperature. After an 
hour, the formalin was removed, and the wells were washed with 60% isopropanol. The 
isopropanol was aspirated, and the wells were allowed to dry completely. Stock Oil Red 
O was made by dissolving 0.175 g of Oil Red O (Sigma-Aldrich, St. Louis, MO; catalog 
#O0625) in 50 mL of isopropanol. Working Oil Red O solution was made with 6 parts of 
Oil Red O stock and 4 parts of deionized water. The working Oil Red O solution was 
added to the wells for 10 minutes at room temperature. The Oil Red O solution was 
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aspirated, and deionized water was used to wash the wells four times. Deionized water 
was added to the wells, and images were then taken under the microscope.  
 
Osteogenic Differentiation and Staining 
 The cells were plated at a density of 4.2 x 104 cells/cm2. Twenty-four hours after 
the cells were plated from the suspension in a 12-well plate, a full growth media change 
was performed. The next morning, the wells were washed twice with PBS, and an 
osteogenic cocktail was added consisting of DMEM, high glucose, supplemented with 
10% FBS, 1% Pen-Strep, 100 nM dexamethasone, 10 nM Alfa Aesar™ sodium β-
glycerophosphate pentahydrate (Fisher Scientific, Hampton, NH; catalog 
#AAL0342514), 0.05 mM 2-phospho-L-ascorbic acid, and 0.2% Normocin™ 
antimicrobial reagent. The sodium β-glycerophosphate pentahydrate and 2-phospho-L-
ascorbic acid were prepared in DMEM, high glucose, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Gibco/Thermo Fisher Scientific, Waltham, MA; 
catalog # 12430054). Osteogenic media was replaced every 3 days for a total of 10 days 
in culture.  
 Before staining the cells with Alizarin Red S, the media was aspirated, and the 
cells were washed twice with PBS. A solution of 4% paraformaldehyde in PBS was used 
to fix the cells for 15 minutes at room temperature. The fixative was removed, and the 
cells were washed three times with deionized water. The deionized water was then 
removed, 2% Alizarin Red S stain solution (ScienCell, Carlsbad, CA; catalog # 0223) 
was added, and the wells were incubated for 20-30 minutes at room temperature. The dye 
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was removed, and the wells were gently washed three times with deionized water. 
Deionized water was then added, and the wells were imaged under a microscope.  
 
Chondrogenic Differentiation and Staining 
 The cells were plated at a density of 7.0 x 104 cells/cm2. Twenty-four hours after 
the cells were plated from the suspension in a 12-well plate, a full growth media change 
was performed. The next morning, the wells were washed twice with PBS, and a 
chondrogenic cocktail was added consisting of DMEM, high glucose, supplemented with 
1% Pen-Strep, 100 nM dexamethasone, 10% Corning™ Insulin-Transferrin-Selenium 
Universal Culture Supplement premix (Fisher Scientific, Hampton, NH; catalog #CB-
40350), 1 μg/mL 2-phospho-L-ascorbic acid, 1% sodium pyruvate (Thermo Fisher 
Scientific, Waltham, MA; catalog # 11360070), 10 ng/mL recombinant human 
transforming growth factor β1 (Thermo Fisher Scientific, Waltham, MA; catalog 
#PHG9204), and 0.2% Normocin™ antimicrobial reagent. The 2-phospho-L-ascorbic 
acid was prepared in DMEM, high glucose, HEPES solution. Chondrogenic media was 
replaced daily for 10 total days in culture.  
 Before staining the cells with Alcian Blue, the media was aspirated, and the wells 
were washed twice with PBS. A solution of 10% formalin was added, and the wells were 
incubated for 1 hour at room temperature. The formalin was removed, and the wells were 
washed twice with deionized water. Five grams of Alcian Blue 8GX (Sigma-Aldrich, St. 
Louis, MO; catalog #A5268-10G) were dissolved in 50 mL of solution comprised of 60% 
absolute ethanol and 40% acetic acid. This staining solution was added to the wells, and 
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the wells were incubated overnight at room temperature in the dark. The next morning, 
the staining solution was aspirated, and the cells were washed twice with a de-staining 
solution comprised of 60% absolute ethanol and 40% acetic acid for 20 minutes each 
time. The de-staining solution was removed, PBS was added, and the wells were imaged 
under the microscope.  
 
Control Growth and Staining 
 Control cells were grown in parallel with the adipogenic, chondrogenic, and 
osteogenic cell lines. The control media consisted of DMEM, high glucose, supplemented 
with 10% FBS, 1% Pen-Strep, and 0.2% Normocin™ antimicrobial reagent. This media 
was changed every other day for a total of 10 days in culture.  
 The control was stained in order to serve as a comparison for the adipogenic, 
osteogenic, and chondrogenic lineages. Therefore, when compared with the adipogenic 
lineage, the control followed the protocol for adipogenic fixation and staining. Similarly, 
control wells followed osteogenic and chondrogenic fixation and staining protocols.  
 
Immunofluorescence Staining 
 Fixation of the cells was performed by aspirating the media and washing twice 
with PBS. The cells were fixed in 4% paraformaldehyde in PBS for 15 minutes at room 
temperature. The fixative was removed, and the cells were washed three times with PBS. 
Permeabilization was performed for 5 minutes at room temperature using 
permeabilization buffer containing 0.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO; 
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catalog #T-9284) and 1% FBS in PBS. The buffer was then discarded, and fresh buffer 
was added for 25 minutes at room temperature. Anti-pan Cadherin antibody was used to 
stain the plasma membrane of all cells to compare morphological changes. 
 For immunofluorescence staining of adipocytes, Adiponectin Monoclonal primary 
antibody (Thermo Fisher Scientific, Waltham, MA; catalog #MA1-054) was diluted 
1:100 in permeabilization buffer, Anti-pan Cadherin antibody (Abcam, Cambridge, MA; 
catalog #ab51034) was diluted 1:100 in permeabilization buffer, and both antibody 
solutions were added to the samples for 2 hours at room temperature. The antibodies 
were then removed, and the samples were washed with permeabilization buffer three 
times. The first wash was done in a 10-minute period, whereas the second and third 
washes were performed for 5 minutes each. Alexa Fluor™ 488 Goat Anti Mouse IgG 
(H+L) (Invitrogen, Carlsbad, CA; catalog #A11029) secondary antibody was diluted 
1:1000 in permeabilization buffer, Alexa Fluor™ 568 Donkey Anti Rabbit IgG (H+L) 
(Invitrogen, Carlsbad, CA; catalog #A10042) secondary antibody was diluted 1:1000, 
and Hoechst 33342 Trihydrochloride, Trihydrate (Invitrogen/Thermo Fisher Scientific, 
Waltham, MA; catalog #H3570) was diluted 1:1000 in permeabilization buffer. These 
secondary antibodies were added to the samples for 1 hour at room temperature. The 
secondary antibodies were removed, and the samples were washed twice for 10 minutes 
with permeabilization buffer. Finally, the samples were washed three times with PBS in 
5-minute periods. The samples were then mounted on slides with ProLong Gold antifade 
reagent (Invitrogen/Thermo Fisher Scientific, Waltham, MA; catalog #2032442).  
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 For immunofluorescence staining of osteocytes, Osteopontin Monoclonal mouse 
primary antibody (Thermo Fisher Scientific, Waltham, MA; catalog #MA5-17180) was 
diluted 1:200 in permeabilization buffer, Anti-pan Cadherin primary antibody was diluted 
1:100 in permeabilization buffer, and both antibody solutions were added to the samples 
for 2 hours at room temperature. The antibodies were then removed, and the samples 
were washed with permeabilization buffer three times. The first wash was done in a 10-
minute period, whereas the second and third washes were performed for 5 minutes each. 
Alexa Fluor™ 488 Goat Anti Mouse IgG (H+L) secondary antibody was diluted 1:1000 
in permeabilization buffer, Alexa Fluor™ 568 Donkey Anti Rabbit IgG (H+L) secondary 
antibody was diluted 1:1000, and Hoechst 33342 was diluted 1:1000 in permeabilization 
buffer. These secondary antibodies were added to the samples for 1 hour at room 
temperature. The secondary antibodies were removed, and the samples were washed 
twice for 10 minutes with permeabilization buffer. Finally, the samples were washed 
three times with PBS in 5-minute periods. The samples were then mounted on slides with 
ProLong Gold antifade reagent.  
 For immunofluorescence staining of chondrocytes, Collagen II Monoclonal 
Antibody (Thermo Fisher Scientific, Waltham, MA; catalog #MA5-12789) was diluted 
1:100 in permeabilization buffer, Anti-pan Cadherin rabbit primary antibody was diluted 
1:100 in permeabilization buffer, and both antibody solutions were added to the samples 
for 2 hours at room temperature. The antibodies were then removed, and the samples 
were washed with permeabilization buffer three times. The first wash was done in a 10-
minute period, whereas the second and third washes were performed for 5 minutes each. 
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Alexa Fluor™ 488 Goat Anti Mouse IgG (H+L) secondary antibody was diluted 1:1000 
in permeabilization buffer, Alexa Fluor™ 568 Donkey Anti Rabbit IgG (H+L) secondary 
antibody was diluted 1:1000, and Hoechst 33342 was diluted 1:1000 in permeabilization 
buffer. These secondary antibodies were added to the samples for 1 hour at room 
temperature. The secondary antibodies were removed, and the samples were washed 
twice for 10 minutes with permeabilization buffer. Finally, the samples were washed 
three times with PBS in 5-minute periods. The samples were then mounted on slides with 
ProLong Gold antifade reagent.  
 
Image Analysis 
 Images were taken on a Zeiss Axiovert 200M microscope (Carl Zeiss 
Microscopy, Peabody, MA). Image processing was performed using ImageJ (FIJI) 
software to analyze a file containing all of the raw images.  
 
RNA Isolation and Extraction 
 After 10 days in culture, the wells were aspirated of media and washed twice with 
PBS. TriPure Isolation Reagent (Sigma-Aldrich, St. Louis, MO; catalog #11667157001) 
was added to the wells, and the wells were incubated at room temperature for 5 minutes. 
A pipette was used to scrape the wells, and the lysate was collected in a microcentrifuge 
tube. A stainless steel bead was added to the microcentrifuge tube, and the sample was 
dissociated using a TissueLyser II (Qiagen, Germantown, MD) for 90 seconds at a 
frequency of 30 s-1. The stainless steel bead was removed, and the tube was spun at 800 
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revolutions per minute (RPM) for 5 minutes. The lysate was then transferred into 
5PRIME phase lock gel-heavy microcentrifuge tubes (Invitrogen, Carlsbad, CA). After 
chloroform was added, the samples were inverted for 15 seconds, incubated for 5 minutes 
at room temperature, and then spun for 15 minutes at 12,000 x g at 4 °C. The clear 
aqueous phase was transferred to a new tube, and 0.5 μL GlycoBlue Co-precipitant 
(Invitrogen, Carlsbad, CA; catalog #AM9515) was added to the tube. Isopropanol was 
then added, and the tube was inverted to mix. The RNA was precipitated overnight at -20 
°C. The next morning, the tube was spun for 30 minutes at 12,000 x g at 4 °C. The 
supernatant was carefully removed so that a small blue pellet was left in the tube. The 
pellet was washed with 80% ethanol and subsequently spun for 10 minutes at 7500 x g at 
4 °C. The ethanol was carefully removed, and the blue pellet was left in the tube. The 
pellet was air dried at room temperature for 15 minutes. The pellet was resuspended in 
UltraPure™ Distilled Water, deoxyribonuclease/ribonuclease (DNase/RNase)-free 
(Invitrogen, Carlsbad, CA; catalog #10977015), and the sample was then measured using 
the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).  
 
Next Generation RNA Sequencing 
 Sequencing was performed using the Illumina NextSeq500 (NextSeq Control 
software v1.2/Real Time Analysis v2.1) platform (Illumina, San Diego, CA). The library 
pool was diluted and denatured according to the standard NextSeq500 protocol, and 
sequencing was carried out to generate single-end 76 base-pair reads using a 75-cycle 
NextSeq500 High-Output Reagent Kit (catalog #FC-404-1005). Reads were mapped 
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against the reference human genome (hg19) using the Dolphin platform 
(https://dolphin.umassmed.edu) provided by the University of Massachusetts 
Bioinformatics Core (University of Massachusetts, Worcester, MA). The RNA-Seq by 
Expectation Maximization (RSEM) method was used to quantify the expression levels of 
genes (Li & Dewey, 2011). 
 
Differential Gene Expression Analysis 
 Comparative analysis between the differentiated samples and the control samples 
was performed based on differential expression (DE) using the DESeq2 method through 
the DEBrowser software (Kucukural, Yukselen, & Ozata, 2019; Love, Huber, & Anders, 
2014). Filtered read counts (containing genes with ≥10 reads for each technical replicate) 
were normalized by DESeq2 through parametric fitting for the estimate of dispersion, and 
the likelihood ratio test was applied for significance testing. A gene was considered to be 
differentially expressed with an absolute log2 fold change greater than 1 and an adjusted 
p-value less than 0.001.  
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RESULTS 
 
Cell Staining  
Osteogenic Differentiation Leads to Calcium Deposition 
 Alizarin Red S staining was used to detect osteogenic differentiation. The dye is 
an anthraquinone dye that stains calcium deposits red. Calcium deposition on stimulated 
progenitor cells suggests effective differentiation into osteocytes (Figure 1F). Non-
stimulated controls were negative for calcium deposition (Figure 1E). 
Chondrogenic Differentiation Causes Glycoprotein Secretion 
 Alcian Blue staining was used to detect chondrogenic differentiation. The dye 
stains glycoproteins in the color blue indicating extracellular matrix formation. 
Glycoprotein secretion on stimulated progenitors suggests effective differentiation into 
chondrogenic cells (Figure 1D). Control cells that were not stimulated displayed low 
levels of glycoprotein secretion (Figure 1C). The staining indicated that the glycoproteins 
secreted as the extracellular matrix of the stimulated cells formed in a nonlinear pattern, 
whereas the low levels of glycoproteins secreted as the extracellular matrix of the control 
cells stained in a linear pattern (Figure 1C,D). 
Adipogenic Differentiation Promoting Lipid Accumulation 
 Oil Red O staining was used to detect adipogenic differentiation. The dye is a 
lysochrome that stains triglycerides and lipids to measure adipogenesis. Imaging 
indicated the presence of adipogenesis and proved differentiation was successful as 
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evidenced by the small and large lipid droplets (Figure 1B). The control group indicated 
no presence of lipid droplets (Figure 1A). 
 
Figure 1. Mesenchymal progenitor cell differentiation dye staining.  
Dye staining was performed for adipogenic, chondrogenic, and osteogenic differentiation. 
(A) Control cells stained with Oil Red O display no lipid accumulation. (B) 
Differentiated cells stained with Oil Red O display several cells with lipid accumulation. 
(C) Control cells stained with Alcian Blue show minor secretion of glycoproteins. (D) 
Differentiated cells stained with Alcian Blue show significant increase in glycoprotein 
secretion. (E) Control cells stained with Alizarin Red S show no calcium deposition. (F) 
Differentiated cells stained with Alizarin Red S show significant areas of calcium 
deposition. All images were taken at a 10X magnification. Scale bar = 100 μm. 
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Osteopontin Indicative of Osteogenesis 
 Osteopontin is a glycoprotein that is implicated in the processes involved with 
bone mineralization. It interacts with integrins and CD44, which are cell adhesion 
molecules. Osteopontin is produced by endothelial cells, osteocytes, osteoblasts, and 
cardiac fibroblasts. It is important in the adhesion of osteocytes to the mineral matrix 
(Denhardt, Noda, & O’Regan, 2001). Osteogenic staining displayed a positive signal for 
osteopontin in the differentiated cells (Figure 2F), but there was also positive staining in 
the control because of the presence of endothelial cells (Figure 2B). Merged images of 
the staining showed osteopontin secretion coinciding with the plasma membrane and 
implicating its role in cellular adhesion (Figure 2H). Morphologically, the differentiated 
cells displayed a similar feature to osteocytes. The presence of long canaliculi connecting 
one osteocyte to another was visible in the staining, as indicated by the arrow in Figure 
5F. 
Collagen II Producing Chondrocytes  
 Collagen II is a fibrillary collagen found in articular and hyaline cartilage. It is 
composed of homotrimers of alpha-1chains of type II collagen (Ricard-Blum, 2011). 
Detection of collagen II would be an indication of chondrogenic differentiation. In the 
differentiated cells, collagen II stained positive and was colocalized near the nuclear 
membrane (Figure 3F). Merged images of differentiated cells showed dense collagen 
staining near the nucleus of the cells (Figure 3H). The control cells also stained positive 
for collagen II (Figure 3B), but the differentiated cells displayed unique staining 
indicative of an extracellular matrix that was collagen dense. The morphology of the 
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differentiated cells also followed the in vitro morphology of chondrocytes. They were 
rounded cells that looked hypertrophic in nature (Figure 5D) as opposed to the control 
cells which maintained the morphology of endothelial cells (Figure 5C).  
Adipocytes Promoting Adiponectin Secretion  
 Adiponectin is a protein hormone secreted by adipocytes. It is involved in glucose 
regulation and fatty acid breakdown (Ahima & Flier, 2000). Adiponectin is an indicator 
of the presence of adipocytes. Staining for adiponectin in the differentiated cells showed 
increased levels of staining indicative of the presence of adipocytes (Figure 4F). The 
control cells also stained for adiponectin (Figure 4B), but the differentiated cells 
displayed clear morphological changes in addition to lipid droplet accumulation in the 
cells (Figure 4A,B). Large lipids were present compared with the control which displayed 
no lipid accumulation (Figure 5A,B).  
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Figure 2. Osteogenic immunofluorescence staining.  
Red staining is for the cadherin plasma membrane protein, green staining is for 
osteopontin, and blue staining is for all nuclei. (D) Merged images of (A), (B), and (C) 
represent control cells. (H) Merged images of (E), (F), and (G) represent differentiated 
cells. (E) Differentiated cells show the distinct morphology of the osteocyte canaliculi 
compared with control (A). (F) Differentiated cells show unique staining patterns along 
the processes of the osteocyte compared with control (B). All images were taken at 40X 
magnification. Scale bar = 25 μm. 
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Figure 3. Chondrogenic immunofluorescence staining.  
Red staining is for the cadherin plasma membrane protein, green staining is for collagen 
II, and blue staining is for all nuclei. (D) Merged images of (A), (B), and (C) represent 
control cells. (H) Merged images of (E), (F), and (G) represent differentiated cells. (E) 
Differentiated cells display a unique morphology with distinct cadherin staining in 
rounded cells compared with control (A). (F) Differentiated cells display significantly 
more staining for collagen II as evidenced by the denser, brighter spots compared with 
control (B). In the merged image (H), there appears to be colocalization of collagen II 
with the nucleus compared with control (D). All images were taken at 40X magnification. 
Scale bar = 25 μm. 
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Figure 4. Adipogenic immunofluorescence staining. 
Red staining is for the cadherin plasma membrane protein, green staining is for 
adiponectin, and blue staining is for all nuclei. (D) Merged images of (A), (B), and (C) 
represent control cells. (H) Merged images of (E), (F), and (G) represent differentiated 
cells. (E) Differentiated cells show the distinct morphology and round lipid droplet 
accumulations compared with control (A). (F) Differentiated cells show a bright stain for 
adiponectin with staining around lipid droplets. Staining of control is also positive, but no 
morphology of adipocytes is seen (B). All images were taken at 40X magnification. Scale 
bar = 25 μm. 
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Figure 5. Mesenchymal progenitor cell immunofluorescence staining.  
All images represent merged images from Figures 2-4 at higher magnification. (A) 
Control cells show clear morphological differences compared with differentiated cells 
(B). The presence of large lipid droplets in (B) (see white arrow) clearly demonstrates 
adipogenic cells. (C) Control cells show clear morphological differences compared with 
differentiated cells in (D). Chondrocytes are larger, and there is a clear collagen II 
staining outside the nucleus (see white arrow). There is also more collagen II staining 
compared with control (C). (E) and (F) display staining of osteopontin, but there are clear 
differences in morphology and density of osteopontin staining. (F) Differentiated cells 
display the typical morphology of an osteocyte and have brighter, more intense 
osteopontin staining compared with control (E). The presence of canaliculus in (F) (see 
white arrow) demonstrates the presence of osteoctyes. All images were taken at 100X 
magnification. Scale bar = 10 μm. 
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RNA Sequencing and Differential Gene Expression 
Adipocytes 
 RNA sequencing of specific adipocyte genes yielded results that indicated higher 
levels of lipoprotein lipase (Figure 6C) and adiponectin (Figure 6D).The level of leptin in 
the adipocytes was low (Figure 6H). Differential gene expression showed significantly 
different expression of adiponectin, lipoprotein lipase, and leptin (Figure 7A). 
Osteocytes  
 RNA sequencing of osteocyte-associated genes yielded results that indicated high 
levels of collagen X alpha type I (Figure 6B), osteonectin (Figure 6F), alkaline 
phosphatase (Figure 6G), and leptin (Figure 6H). Osteopontin levels were lower in 
osteocyte-associated genes compared with control (Figure 6I). Differential gene 
expression showed significantly higher levels of osteonectin and alkaline phosphatase 
transcription, and a lower level of osteopontin that was still significantly expressed 
(Figure 7C). 
Chondrocytes  
 RNA sequencing of chondrocyte-associated genes demonstrated high levels of 
aggrecan (Figure 6A), collagen X alpha type 1 (Figure 6B), and collagen II alpha type 1 
(Figure 6E). Differential gene expression showed significantly higher levels of aggrecan 
and collagen X alpha type 1 (Figure 7B). No results were obtained for collagen II alpha 
type 1 because of low fold changes. 
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Figure 6. RNA sequencing analysis on control, adipocytes, chondrocytes, and 
osteocytes. 
Transcripts per kilobase million (TPM) were measured for control (blue), adipogenic 
(gold), chondrogenic (orange), and osteogenic (green) lineages. Genes were looked at for 
(A) aggrecan (ACAN), (B) collagen X alpha type 1 (COL10A1), (C) lipoprotein lipase 
(LPL), (D) adiponectin (ADIPOQ), (E) collagen II alpha type I (COL2A1), (F) 
osteonectin (SPARC), (G) alkaline phosphatase (ALPL), (H) leptin (LEP), and (I) 
osteopontin (SPP1). RNA sequencing was carried out on a single replicate, and thus 
statistical analysis was not performed.  
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Figure 7. Differential gene expression analysis. 
Expression of genes was compared between the differentiated cell line and the control. 
Colored dots represent genes noted to be differentially expressed with an absolute log2 
fold change greater than 1 and an adjusted p-value less than 0.001. (A) Comparison of 
differentiated adipocytes with control shows a significant increase in gene expression of 
ADIPOQ (adiponectin), LPL (lipoprotein lipase), and LEP (leptin). (B) Comparison of 
differentiated chondrocytes with control shows a significant increase in COL10A1 
(collagen X alpha type I) and ACAN (aggrecan), indicating differentiation to the 
chondrogenic lineage. (C) Comparison of osteocytes with control shows increased levels 
of SPARC (osteonectin) and ALPL (alkaline phosphatase). These genes are important 
proteins secreted by bone. The level of SPP1 (osteopontin) results in a negative fold 
change that is still considered to be differentially expressed.  
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DISCUSSION 
 
 This study showed that mesenchymal progenitor cells collected from human 
subcutaneous adipose tissue can be cultured in vitro and differentiated into osteogenic, 
chondrogenic, and adipogenic cells. The cells displayed the capacity to differentiate; 
however, utilizing them as a therapeutic is an area that needs to be assessed and 
optimized. Further work is recommended to understand the process of differentiation and 
to determine how these cells could potentially work as a tissue.  
 
Adipogenic Lineage 
Oil Red O staining of lipid droplets in stimulated cells displayed characteristics of 
adipocyte differentiation (Figure 1B), and positive staining of adiponectin indicated clear 
lipid accumulation (Figure 4F). These data were supported by genomic data showing 
lipoprotein lipase, adiponectin, and leptin to be differentially expressed in comparison 
with control groups (Figure 7A). Lipoprotein lipase and adiponectin also had higher 
levels of mRNA expression, whereas leptin was elevated but not to the extent of 
lipoprotein lipase and adiponectin (Figure 6C,D,H). Taken as a whole, these results 
suggest that differentiation into adipocytes was successful. This is supported by lineage 
tracing done in other studies that showed that both white and brown fat cells can originate 
in the vascular endothelium of adipose tissue, suggesting that it is a plentiful source of 
progenitor cells (Tran et al., 2012).  
 38 
This insight has led to promising research. “Beige” adipocytes, which are 
considered to be the type of adipocytes associated with metabolically healthy phenotypes, 
were found to display comparable thermogenic capabilities to brown adipocytes (Wu et 
al., 2012). Other studies revealed that progenitor cells from capillary networks could be 
grown in vitro and differentiated into white adipocytes that could be further stimulated to 
differentiate into “beige” adipocytes (Min et al., 2016).  Evidence suggesting that “beige” 
adipocytes are in fact metabolically active and may potentially decrease the risk of 
developing metabolic disease spurred further investigation (Corvera & Gealekman, 
2014). The “beige” adipocytes that were developed from capillary networks were 
implanted in a mouse model. The mice exhibited improved metabolic homeostasis 
through lower fasting glucose levels and a more rapid glucose disposal rate (Min et al., 
2016). This opens the potential for using in vitro cultured adipocytes as a therapeutic to 
treating metabolic diseases.  
In order to understand how adipose tissue can be beneficial, it is essential to look 
at the mechanisms of how adipose tissue works. The secretion of hormones is critical in 
adipose tissue dynamics. Adiponectin and leptin are important modulators of metabolism 
and lipid regulation (Ahima & Flier, 2000). Adiponectin, especially, is a hormone of 
immense interest as it is the most abundant peptide secreted by adipocytes. Because low 
levels of adiponectin have been discovered in obesity, replacement therapy has been an 
area investigated in regard to treatment (Arita et al., 1999). Leptin, a hormone responsible 
for the control of hunger by inhibiting feeding, was found to be expressed in low levels 
(Ahima and Flier, 2000). Therapies targeting these hormones through progenitor 
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differentiation open the possibility of treating metabolic diseases and obesity in a new 
manner. 
 
Chondrogenic Lineage 
Positive staining of glycoproteins indicated the presence of secreted extracellular 
matrix glycoproteins (Figure 1D) and supported the belief that chondrogenic 
differentiation was occurring. The mRNA levels of aggrecan, collagen X alpha type 1, 
and collagen II alpha type I were elevated in chondrocyte samples (Figure 6A,B,E). 
Collagen II localization near the nucleus of the cell provided support for the production 
and extensive processing that must occur in the Golgi of the cell (Figure 3F,H and Figure 
5D). 
Studies performed on in vitro chondrogenesis have resulted in functioning 
chondrocytes capable of producing collagen and aggrecan, components of the 
extracellular matrix in cartilage. Notably, the chondrocytes made collagen X, which is 
implicated in the growth, development, and remodeling of articular cartilage and in 
facilitating endochondral ossification (Shen, 2005). Another study based on progenitor 
differentiation demonstrated that chondrocytes could be injected in the back of mice and 
were capable of producing hyaline cartilage (Jiang et al., 2016).  
Considering that these cartilages are found within joints, they have become targets 
for a therapeutic model in clinical situations, particularly because cartilage is avascular 
and lacks the capacity to heal itself. Regenerative medicine focusing on in vitro 
chondrocyte differentiation and subsequent implantation has been investigated as a 
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treatment for osteoarthritis. However, one factor to consider during the discussion of 
regenerative medicine is that some patients may already have medical devices in their 
joints. A reasonable question is whether chondrocytes differentiated in vivo would be 
compatible with those devices. A study performed on spherical shoulder implants 
demonstrated that primary chondrocytes could be grown on biomedical devices and 
maintained with media for bone-like conditions or cartilage-like conditions (Hannoun et 
al., 2019). Understanding the mechanisms of in vitro differentiation of progenitor cells 
into fully functional chondrocytes opens the possibility of applying this knowledge to 
regenerative medicine techniques.  
 
Osteogenic Lineage 
Positive staining with Alizarin Red S indicated the presence of calcium deposits 
and provided support that mineralization of the collagen matrix was occurring (Figure 
1F). Osteonectin mRNA levels were increased and differentially expressed, further 
validating genomic alterations leading to mineralization (Figures 6F and 7C). The mRNA 
levels of the extracellular linking protein osteopontin were low and significantly reduced 
compared with the control (Figures 6I and 7C). This is supportive of osteogenic 
differentiation as osteopontin is the only osteoblast-related gene that is downregulated in 
mature bone matrix-producing osteoblasts (Denhardt et al., 2001). Immunofluorescence 
imaging showed that osteopontin was linked to the osteocyte cell itself as well as the 
canaliculi, providing evidence of structural linkage to the matrix (Figure 2F,H and Figure 
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5F). Also, levels of leptin mRNA were elevated and differentially expressed in osteocytes 
(Figure 6H).  
Leptin is essential in stimulating bone formation, growth, and remodeling 
peripherally by acting on leptin receptors on osteoblasts (Steppan, Crawford, & Chidsey-
Frink, 2000). It does so by activating the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signaling pathway to induce osteocyte differentiation and 
proliferation through the release of cytokines such as interleukin-6 and interleukin-11 (Li, 
2013). This action allows bone to heal itself after injury, a complex process that includes 
inflammation, repair, and remodeling (Oryan, Kamali, & Moshiri, 2017). Hormones are 
critical components for adaptive needs such as growth, repair, and crisis adaptation (Ebert 
et al., 2007). However, this ability may be hindered in certain circumstances. 
In order to cope with this problem, research has been done to find treatments for 
bone disorders. Bone tissue-engineered constructs were found to be efficient forms of 
treatment for large bone defects in normal and osteoporotic bone in animals (Poser et al., 
2014).  Autograft is considered the ideal therapeutic because it provides osteoinductive 
growth factors, bone-specific cells, and an osteoconductive scaffold (Giannoudis, 
Dinopoulos, & Tsiridis, 2005). Medical devices generally do not have these properties. 
Therefore, the use of progenitor cells to stimulate osteogenesis has become an interesting 
area of research. Implants loaded with autologous mesenchymal cells were found to assist 
in the healing of canine segmental bone defects (Bruder, Kraus, Goldberg, & Kadiyala, 
1998). In a study done on immunocompromised animals that had osseous defects, human 
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mesenchymal progenitors were able to form bone with sufficient mechanical integrity 
(Bruder, Jaiswal, et al., 1998).  
Mechanical integrity is an important component of bone function and requires 
extensive scaffolding, mineralization, and networking. Osteocyte-differentiated cells 
displayed this mechanical component through high levels of alkaline phosphatase 
transcription. An elevated level would be expected because bone alkaline phosphate is 
used in the calcification of bone matrix. Similarly, proof of the bone matrix being formed 
is evidenced by the presence of collagen X. Collagen X is associated with endochondral 
ossification and has been implicated in regulating matrix mineralization (Shen, 2005). 
This is critically important to bone, particularly because collagen orientation is vital to 
preventing damage to bone integrity (Ascenzi, Gill, & Lomovtsev, 2008).  
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CONCLUSION 
 
 Mesenchymal progenitor cells were collected from human adipose tissue. The 
cells extracted from the adipose tissue displayed the capacity to differentiate into 
osteogenic, chondrogenic, and adipogenic lineages. RNA sequencing gave an insight into 
the genomic expression, and the expression of lineage-specific genes was prevalent. The 
results indicated that adipose tissue can be a source of mesenchymal progenitor cells and 
that differentiation of osteocytes, chondrocytes, and adipocytes can be performed in vitro. 
Further research should be done to assess whether these cells can produce fully functional 
tissues as a means of therapeutic intervention for diseases related to the mesenchyme.  
 
Limitations of the Study 
 Although compelling data were collected in this experiment to confirm the 
presence of differentiation into osteocytes, chondrocytes, and adipocytes, there are 
limitations to this study. This work proved that differentiation is possible; however, it did 
not prove that these cells are capable of forming fully functional tissues that could be 
useful as a therapeutic. The ability of the differentiated cells to replicate was not 
analyzed. When the mesenchymal progenitor cells were grown in endothelial growth 
media, the cells were capable of dividing and expanding. However, when the cells were 
placed in differentiation media, the replicative capacity of the cells was not considered. It 
is uncertain whether any of the lineages would continue to replicate in differentiation 
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media. Thus, a limitation in potentially using these cells as a therapeutic may be the 
capability to isolate the differentiated cells and then replicate them. 
 Another major limitation in this study is that it was not tested whether a single 
cell that differentiated into a specific lineage had the capacity to differentiate into a 
different lineage. For example, a cell that differentiated into an adipocyte was not 
evaluated in terms of whether it could differentiate into an osteocyte. One possible 
method of determining this would be to see if dedifferentiation is possible. Theoretically, 
cells could be given differentiation media and then dedifferentiated back into progenitor 
cells. Previous studies demonstrated the capacity for dedifferentiation of articular 
chondrocytes, as evidenced by the loss of chondrocyte-specific molecular markers (Caron 
et al., 2012). Those progenitor cells could then been placed in a different differentiation 
media and evaluated for their ability to differentiate into each lineage.  
 One of the major limitations with the differentiation protocols is the accumulation 
of lipid droplets in the osteogenic and chondrogenic lineages. The osteogenic and 
chondrogenic differentiation protocols required the use of dexamethasone, which is one 
of the important components of the adipogenic differentiation (Langenbach & Handschel, 
2013). As a side effect of using dexamethasone in the other differentiation protocols, 
lipid droplets were found. These lipid droplets were more prevalent in the osteogenic 
differentiation than in the chondrogenic differentiation based on the levels of leptin 
found. A study performed on mice demonstrated that dexamethasone at 100 mM strongly 
caused adipogenic differentiation but was also responsible for producing osteogenic 
differentiation (Ghali et al., 2015). Optimizing the dexamethasone concentration to limit 
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adipogenic differentiation would be an area of interest. By limiting adipogenic 
differentiation, a revised protocol may improve the possibility to induce more efficient 
osteogenic differentiation.  
 
Future Studies 
 Future studies on this topic should include a clone project. The idea behind the 
clone project would be to take single cells and attempt to differentiate them into the 
different lineages. In the differentiation of the cells in this study, there was low efficiency 
of differentiation in certain lineages, although the effect was not quantified. Thus, it 
would be interesting to see if one cell that had differentiated into an adipocyte also had 
the ability to differentiate into a chondrocyte or an osteocyte. In addition, growing the 
cells in this study led to a heterogeneous mixture of differentiated cells and 
undifferentiated cells. If possible, it would be worthwhile to try to culture a homogenous 
population of cells.  
 Another future study should evaluate the viability of the chondrogenic or 
osteogenic cells in a mouse model. If a mouse with osteoporosis was injected with 
osteocytes, it would be interesting to see whether the mouse could have improvements in 
relation to the disease. Likewise, if a mouse had cartilage damage in the joints, the 
implantation of chondrocytes to promote healing and joint functionality would be 
beneficial to explore.  
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